Movement toward a paradigm shift in breast cancer from reactive treatment to prevention could gain support from the long-term results of the Study of Tamoxifen and Raloxifene (STAR) trial. Based on the updated results of the STAR trial, presented at the American Association for Cancer Research, AACR President-elect Judy Garber and other experts at a press briefing argued that there should be wider use of medications to prevent breast cancer, just as drugs are commonly used to ward off other major...